Immix Biopharma | Investor Presentation Deck | 56 slides · page 35 of 56
The table highlights low incidence of severe adverse events and management protocols for NXC-201.
Pitch deck · appendix_data · analyze_data · balanced density
Slide locked Sign in to view
Slide schematic 3/3
disclaimer 1/1 table 1/1 title 1/1
Components 3
disclaimer data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.